1. Home
  2. PAXS vs RLMD Comparison

PAXS vs RLMD Comparison

Compare PAXS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Access Income Fund of Beneficial Interest

PAXS

PIMCO Access Income Fund of Beneficial Interest

HOLD

Current Price

$14.67

Market Cap

673.8M

Sector

Finance

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.28

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAXS
RLMD
Founded
N/A
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
673.8M
661.9M
IPO Year
2021
2012

Fundamental Metrics

Financial Performance
Metric
PAXS
RLMD
Price
$14.67
$6.28
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$12.40
AVG Volume (30 Days)
167.2K
2.3M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
N/A
N/A
Revenue
N/A
$13,070.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
154.83
52 Week Low
$13.74
$0.55
52 Week High
$16.56
$8.00

Technical Indicators

Market Signals
Indicator
PAXS
RLMD
Relative Strength Index (RSI) 68.57 42.80
Support Level $14.30 $6.17
Resistance Level $14.86 $7.34
Average True Range (ATR) 0.17 0.45
MACD 0.07 0.01
Stochastic Oscillator 93.90 1.75

Price Performance

Historical Comparison
PAXS
RLMD

About PAXS PIMCO Access Income Fund of Beneficial Interest

PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: